Analystreport

Navidea Biopharmaceuticals, Inc. (NASDAQ: NAVB) had its "buy" rating re-affirmed by analysts at HC Wainwright.

Navidea Biopharmaceuticals, Inc.  (NAVB) 
NASDAQ:AMEX Investor Relations: ir.navidea.com